Michael Wacker

USPTO Granted Patents = 13 (Patent Applications = 8)

CIPO Patents = 8 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 14)

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 48(Granted Patents)

Company Filing History:

7 out of 531

Glaxosmithkline Biologicals Sa

Years Active: 2014-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12398380 - Methods of host cell modification (2025-08-26),

2. 11944675 - Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells (2024-04-02),

3. 11220676 - Methods of host cell modification (2022-01-11),

4. 10973901 - Production of recombinant vaccine inby enzymatic conjugation (2021-04-13),

5. 10835592 - Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells (2020-11-17),

6. 10307473 - Capsular gram-positive bacteria bioconjugate vaccines (2019-06-04),

7. 10195262 - [object Object] (2019-02-05),

8. 9764018 - Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells (2017-09-19),

9. 9585950 - Capsular gram-positive bacteria bioconjugate vaccines (2017-03-07),

10. 8895014 - Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells (2014-11-25),

11. 8871491 - Capsular gram-positive bacteria bioconjugate vaccines (2014-10-28),

12. 8846342 - Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells (2014-09-30),

13. 8703471 - System and method for the production of recombinant glycosylated proteins in a prokaryotic host (2014-04-22),

Title: The Innovations of Inventor Michael Wacker

Introduction

Michael Wacker, an accomplished inventor based in Unterengstringen, Switzerland, has made significant contributions to the field of biotechnology. Holding a total of 12 patents, his work primarily revolves around bioconjugates and methods of host cell modification, showcasing his expertise in protein engineering and genetic manipulation.

Latest Patents

One of Michael Wacker's noteworthy recent patents involves bioconjugates made from recombinant N-glycosylated proteins derived from procaryotic cells. This invention focuses on a bioconjugate vaccine, such as an O1-bioconjugate vaccine, which includes a protein carrier with a specific consensus sequence. Additionally, the bioconjugate is linked to at least one antigenic polysaccharide from a pathogenic bacterium and may include an adjuvant for enhanced immunogenicity.

Another significant patent by Wacker outlines methods of inserting nucleic acid sequences into host cells. This invention not only describes the techniques to create genetically stable host cells with inserted nucleic acid sequences but also discusses their application in the generation of proteins.

Career Highlights

Throughout his career, Michael Wacker has been associated with prominent companies in the biotechnology sector. He has notably worked at GlaxoSmithKline Biologicals SA, where he contributed to advancements in vaccine development, and Glycovaxyn AG, focusing on innovative glyco-engineering solutions.

Collaborations

Michael Wacker has collaborated with fellow professionals in his field, including Michael T. Kowarik and Michael L. Wetter. These partnerships have helped enhance his research and lead to impactful innovations in biotechnology.

Conclusion

Michael Wacker stands out as a prolific inventor whose patents and innovations continue to influence the domain of bioconjugates and genetic engineering. His dedication to advancing biotechnology through collaboration and innovation underscores the essential role inventors play in scientific progress.

This text is generated by artificial intelligence and may not be accurate.